Kyowa Hakko and LEO Pharma partner on topical calcipotriol/betamethasone dipropionate in Japan

26 December 2013

Japanese drugmaker Kyowa Hakko Kirin (TYO: 41521) and Denmark’s privately-held dermatology specialist LEO Pharma have entered into a distribution and co-promotion agreement for LEO’s proprietary topical calcipotriol/betamethasone dipropionate combination product. LEO had filed for the manufacturing and marketing approval of this product for psoriasis vulgaris in Japan in August 2013.

The Danish firm first developed and launched this product in Denmark in 2001 as a topical treatment for psoriasis vulgaris. The product is now approved and marketed in 97 countries worldwide, including the USA, and is widely used as the first-line treatment for psoriasis vulgaris. Japanese subsidiary LEO Pharma KK filed for the marketing and manufacturing approval of this product with the Ministry of Health, Labor and Welfare (MHLW) in Japan in August 2013 as the first topical active vitamin D3/steroid combination drug (once daily application) for the treatment of psoriasis.

Financial terms of the deal

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK